Nanobac signs letter of intent for acquisition of DNAPrint Genomics

With the acquisition, which is subject to DNAPrint Genomics shareholder approval, Nanobac becomes one of a select group of next-generation drug and diagnostics developers, applying advanced computational methods and systematic genome-based approaches to streamline clinical product development.

The combined company would have annualized revenue of approximately $5 million, developing drug pipeline and product development collaborations with Harvard/Beth Israel Deaconess Medical Center, Mayo Clinic, Cleveland Clinic and Emory University.

Benedict Maniscalco, co-chairman and chief medical officer of Nanobac Pharmaceuticals, said: “Combining our diagnostic portfolios, specifically DNAP’s Protectin and Nanobac’s NB2 has the potential to play a significant role in the early diagnosis of vascular disease and could potentially help in identifying early signs and progression of cardiovascular disease.”